Bioactive C17 and C18 acetylenic oxylipins have been shown to inhibit NF-κB and the formation of proinflammatory cytokines and inflammatory enzymes such as ILs, COXs and LOXs and, therefore, the direct inhibition of these inflammatory mediators appears to be another important mechanism of action for the prevention and treatment of cancer by these secondary metabolites. Here, NFKB1 is linked to cancer.